Conclusion
Concurrent chemoradiotherapy has good short-term and long-term efficacy for patients with metastatic and recurrent HCC. It greatly improves patients' quality of life and down-regulates VEGF and COX-2 expression.
Methods
This is a retrospective analysis. Data from 60 patients with metastatic and recurrent HCC admitted from Oct. 2020 to Feb. 2021 were chosen and grouped according to the treatment plans. Each group contained 30 cases. The control group was treated with chemotherapy, and the observation group received concurrent chemoradiotherapy. The two groups were treated continuously for two rounds, with 21 days in each round. The therapeutic efficacy, toxic side effects, pre- and post-treatment quality of life, changes in vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2), and survival during follow-up were compared between the two groups.
Objective
This study retrospectively analyzed the effect of concurrent chemoradiotherapy on prognosis and quality of life of patients with metastatic and recurrent hepatocellular carcinoma (HCC).
Results
The total therapeutic efficacy of the observation group was higher than that of the control group (P<0.05). The post-treatment Karnofsky score in the observation group was higher than that in the control group (P<0.05). The post-treatment protein expressions of VEGF and COX-2 and peripheral blood mononuclear cells were lower than those before treatment in the two groups (P<0.05), and were lower in the observation group than those in the control group (P<0.05). The observation group had superior survival times than the control group (P<0.05).